Abstract
Candida albicans is an opportunistic pathogenic fungus capable of causing infections in an expanding population of immunosuppressed patients. The implementation of proteomics in the post-genomic era of this organism can provide vital information about its biological complexity and pathogenic traits. C. albicans proteomic analyses to date have focused on the understanding of the cell wall, virulence, dimorphism, antifungal drug effects and resistance, and serological response, among others. This exciting and rapid growing discipline should become an indispensable tool in C. albicans research, particularly to address problems that cannot be solved by genomic studies. Furthermore, in the near future it is expected that results from proteomic experiments will lead to novel techniques for the management of candidiasis.
Keywords: Candida albicans, two-dimensional electrophoresis, proteomics, serology, cell wall, immunoproteomics, adhesins, morphogenesis, antifungal resistance
Infectious Disorders - Drug Targets
Title: Proteomics to Study Candida albicans Biology and Pathogenicity
Volume: 6 Issue: 4
Author(s): Derek P. Thomas, Aida Pitarch, Lucia Monteoliva, Concha Gil and Jose L. Lopez-Ribot
Affiliation:
Keywords: Candida albicans, two-dimensional electrophoresis, proteomics, serology, cell wall, immunoproteomics, adhesins, morphogenesis, antifungal resistance
Abstract: Candida albicans is an opportunistic pathogenic fungus capable of causing infections in an expanding population of immunosuppressed patients. The implementation of proteomics in the post-genomic era of this organism can provide vital information about its biological complexity and pathogenic traits. C. albicans proteomic analyses to date have focused on the understanding of the cell wall, virulence, dimorphism, antifungal drug effects and resistance, and serological response, among others. This exciting and rapid growing discipline should become an indispensable tool in C. albicans research, particularly to address problems that cannot be solved by genomic studies. Furthermore, in the near future it is expected that results from proteomic experiments will lead to novel techniques for the management of candidiasis.
Export Options
About this article
Cite this article as:
Thomas P. Derek, Pitarch Aida, Monteoliva Lucia, Gil Concha and Lopez-Ribot L. Jose, Proteomics to Study Candida albicans Biology and Pathogenicity, Infectious Disorders - Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/187152606779025815
DOI https://dx.doi.org/10.2174/187152606779025815 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Promises and Challenges of Adult Stem Cells in Cancer Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anti-Tumor Activity of Non-Nucleosidic Reverse Transcriptase Inhibitors
Current Pharmaceutical Design In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Current Cancer Therapy Reviews Osteoimmunology and Beyond
Current Medicinal Chemistry Circumventing Melanoma Chemoresistance by Targeting DNA Repair
Current Medicinal Chemistry Anemia in Chronic Heart Failure - Clinical and Prognostic Significance
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Dasatinib in the Treatment of Chronic Myeloid Leukemia
Current Signal Transduction Therapy ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design Interstitial Lung Disease in Systemic Lupus Erythematosus, Sjogren’s Syndrome, and Mixed Connective Tissue Disease
Current Respiratory Medicine Reviews HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Editorial(Hot Topic:Targeting the Ubiquitin-Proteasome Pathway - Current Perspectives and Future Directions)
Current Pharmaceutical Design Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism Editorial [Hot Topic: Targeting Tumor Uniquitin-Proteasome Pathway with New and Old Drugs (Guest Editor: Q. Ping Dou)]
Current Cancer Drug Targets Banking Strategies for Improving the Hematopoietic Stem Cell Content of Umbilical Cord Blood Units for Transplantation
Current Stem Cell Research & Therapy Combined Effect of Parthenolide and Various Anti-cancer Drugs or Anticancer Candidate Substances on Malignant Cells in vitro and in vivo
Mini-Reviews in Medicinal Chemistry